Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors. Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A ...
Welcome to this exciting webinar: Optimize your PCR, where we will delve into the intricacies of this powerful molecular biology technique. Our speaker, Gabriel Almeida Alves, BSN, MS, PhD, will take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results